地诺单抗怎么使用？

How to use? Denosumab usage and dosage: (1) Xgeva can only be injected subcutaneously, not intravenously, intramuscularly or intradermally. (2) Solid tumor bone metastasis: 120mg once every 4 weeks, injected subcutaneously in the upper arm, thigh or abdomen. (3) Giant cell tumor of bone: 120 mg once every 4 weeks, subcutaneous injection, and then 120 mg on d8 and d15 in the first month of treatment. (4) Administer calcium and vitamin D appropriately to prevent hypocalcemia. (5) Malignant hypercalcemia: 120 mg once every 4 weeks, subcutaneous injection, and then 120 mg on d8 and d15 in the first month of treatment. The medication is injected under the skin in the upper arm, thigh, or abdomen.

Precautions when taking denosumab: (1) Hypocalcemia and severe hypocalcemia may occur in patients receiving Xgeva. Correct hypocalcemia before starting Xgeva. Monitor calcium levels and appropriately supplement all patients with calcium and vitamin D. (2) Osteonecrosis of the jaw may occur in patients receiving Xgeva. Have an oral examination before starting Xgeva. Monitor for symptoms. Avoid Invasive Dental Surgical Adverse Reactions During Treatment with Xgeva The most common adverse reactions (incidence greater than or equal to 25% of patients per case-patient) receiving Xgeva were fatigue/asthenia, hypophosphatemia, and nausea.

(denosumab, also known as AMC-162, trade name Prolia) is a bone resorption inhibitor with a unique mechanism of action. It specifically targets the receptor activator of NF-kB ligand (RANKL), inhibits the activation and expansion of osteoclasts, reduces bone resorption, and increases bone density. On May 28, 2010, the European Commission approved this product for the treatment of bone loss related to hormone suppression in postmenopausal women with osteoporosis and prostate cancer patients. It can also be used in patients who are currently ineffective or intolerant to other treatments to reduce the risk of fractures in patients.